Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes | Latest News RSS feed

Sglt2 Inhibitors Are Associated With Reduced Cardiovascular Disease For Patients With Type 2 Diabetes - Latest News


ACC offers guidance on using diabetes drugs for CV event reduction

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients w... read more

Cardiovascular Results for Dapagliflozin Point to SGLT2 Use to Prevent Heart Failure

the possibility that SGLT2 inhibitors might be used to prevent heart failure in patients with type 2 diabetes. Results from the 17,000-patient cardiovascular outcomes trial for dapagliflozin, the sodi... read more

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

However the DPP-4 inhibitor drugs were not associated with a reduced risk of mortality compared to people taking placebo or no treatment at all. Furthermore, SGLT-2 inhibitor ... "Patients with type 2 ... read more

Looking for another news?


Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

New data showed that empagliflozin reduced the risk of cardiovascular ... type 2 diabetes and peripheral artery disease.” Empagliflozin (marketed as Jardiance ®) is an oral, once daily, highly selecti... read more


AMPK Activator O304 A Novel Potential Treatment for Diabetic Kidney Disease

Globally ~40% of type 2 diabetes ... vascular system to reduce hyperfiltration. SGLT2 inhibitors are recently introduced anti-hyperglycaemic agents that show improved renal outcome in T2D patients wit... read more

Have Diabetes? New Drugs Can Help You Pee Out Excess Sugar

An added benefit is that SGLT2 inhibitors are associated with modest weight loss. For instance, patients shed from 2.8 percent to 5.7 ... a concern because patients with diabetes are already at increa... read more

AstraZeneca announces CVD-REAL study of patients with T2D confirms CV benefits associated with SGLT-2 inhibitors

and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines. The results were pres... read more

AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market

AstraZeneca announced positive results for type 2 diabetes patients with renal impairment who were treated with its SGLT2 inhibitor FARXIGA ... since it has shown to reduce the risk of advance renal i... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Dapagliflozin is not indicated to reduce ... Events in Type 2 Diabetes. New England Journal of Medicine. 2017. DOI: 10.1056/NEJMoa1611925. 9.Kosiborod M, et al. Lower risk of heart failure and death i... read more

Effect of Elevated Triglycerides on Glycemic Management by Patients with Type 2 Diabetes

The CNHSS includes people with type 2 who are at least 18 years of age but excludes those whose diabetes is secondary to another disease ... are strongly associated with increased risk of inadequate g... read more

Higher risk for amputation, DKA with SGLT2 inhibitors for T2DM

(HealthDay)—Use of sodium glucose cotransporter 2 (SGLT2) inhibitors is associated with an increased risk for lower-limb amputation and diabetic ketoacidosis compared with use of glucagon-like peptide ... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established cardiovascular disease ... Events and Death Associated with Initiation o... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us